Substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds for use in the treatment of neuropathic pain

Substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds address synaptic misconnections and inflammation to treat neuropathic pain, offering effective pain relief in nerve injury models.

JP7595033B2Active Publication Date: 2024-12-05KINGS COLLEGE LONDON
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021570750
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-30
Filing Date
2020-05-29
Publication Date
2024-12-05
Estimated Expiration
2040-05-29

AI Technical Summary

Technical Problem

Current treatments for neuropathic pain, such as tricyclic antidepressants and antiepileptic drugs, often fail to address the underlying synaptic misconnections caused by nerve injuries, leading to chronic and debilitating pain.

Method used

The use of substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (BOBA compounds) that induce axonal outgrowth and modulate inflammatory pathways to treat and prevent neuropathic pain.

Benefits of technology

BOBA compounds effectively reduce mechanical and thermal hypersensitivity in neuropathic pain models by promoting accurate synaptic connections and reducing inflammation, providing unexpected pain relief.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007595033000038
    Figure 0007595033000038
  • Figure 0007595033000039
    Figure 0007595033000039
  • Figure 0007595033000040
    Figure 0007595033000040
Patent Text Reader

Abstract

The present invention relates generally to the field of therapy. More specifically, the present invention relates to certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (collectively referred to herein as BOBA compounds) and pharmaceutical compositions containing these compounds for use in methods for the treatment or prevention of neuropathic pain. (Formula (A)) [Formula 1] TIFF2022534594000034.tif20150
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] (Related Applications) This application is related to UK Patent Application No. 1907647.0, filed May 30, 2019, the contents of which are incorporated herein by reference in their entirety.

[0002] The present invention relates generally to the field of therapy. More specifically, the present invention relates to certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (collectively referred to herein as BOBA compounds) and pharmaceutical compositions comprising such compounds for use in methods for the treatment or prevention of neuropathic pain. [Background technology]

[0003] Numerous publications are cited herein in order to more fully describe and disclose the invention and the state of the art to which this invention pertains. Each of these publications is herein incorporated by reference in its entirety into this disclosure to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference.

[0004] Throughout this specification, including the claims which follow, unless the context otherwise requires, the word "comprise" and variations such as "comprises" and "comprising" will be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps.

[0005] It must be noted that as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "pharmaceutical carrier" includes mixtures of two or more such carriers, and the like.

[0006] Often, ranges are expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values ​​are expressed as approximations, it will be understood that the particular value forms another embodiment by use of the antecedent "about."

[0007] This disclosure includes information that may be useful in understanding the present invention. This is not an admission that any of the information provided herein is prior art or relevant to the invention(s) claimed herein, or that any publication specifically or implicitly mentioned is prior art.

[0008] (Neuropathic pain) Neuropathic pain is a chronic condition secondary to a lesion or disease of the somatosensory nervous system, affecting 7–10% of the population (see, e.g., Colloca et al., 2017 ).

[0009] In chronic pain populations, neuropathic pain is found, for example, in postherpetic neuralgia, painful diabetic polyneuropathy, post-surgical neuropathic pain, multiple sclerosis, spinal cord injury, stroke, and cancer (see, for example, Colloca et al., 2017). Clinically most important painful generalized peripheral neuropathies include those associated with, for example, diabetes, prediabetes, and other metabolic dysfunctions; infectious diseases (mainly HIV infection and leprosy); chemotherapy; immune and inflammatory disorders (e.g., Guillain-Barré syndrome); inherited neuropathies and channelopathies (e.g., hereditary erythromelalgia, a disorder in which blood vessels are accidentally blocked and subsequently engorged and inflamed; see, for example, Colloca et al., 2017).

[0010] Neuropathic pain has two main characteristics: (1) hyperalgesia - increased pain resulting from stimuli that normally evoke pain; and (2) allodynia - pain resulting from stimuli that normally do not evoke pain (see, e.g., Jensen et al., 2014).

[0011] There are thought to be at least two distinct modes of development of these features: (a) peripheral sensitization, which involves changes in the threshold of peripheral nociceptors, including the potential for spontaneous firing, and (b) central sensitization, in which there are changes in reactivity at central synapses that transmit pain sensations, particularly in the dorsal horn of the spinal cord.

[0012] The importance of central sensitization and whether it depends on peripherally sensitized inputs for its maintenance remains controversial (see, e.g., Meacham et al., 2017). Nevertheless, the occurrence of mechanical allodynia, in which activation of Aβ mechanoreceptor fibers induces pain, rather than its reduction, is clear evidence of a central change, due in part to the release of brain-derived neurotrophic factor (BDNF) in the dorsal horn. This is thought to cause two effects: (1) mechanoreceptor inputs increase the GABA reversal potential (E GABA ) to be excitatory rather than inhibitory to neurons transmitting pain sensations; and (2) a reduced effect of presynaptic inhibition on nociceptive afferent fibers (see, e.g., Chen et al., 2014 ).

[0013] In accordance with these results, a single intrathecal injection of BDNF produces pain for 48 days that subsequently resolves (see, e.g., Constandil et al., 2011), thus suggesting the presence of long-lasting, although not permanent, central changes.

[0014] (Treatment of neuropathic pain) Neuropathic pain is commonly managed with tricyclic antidepressants (e.g., amitriptyline, nortriptyline, desipramine) or with certain antiepileptic drugs (e.g., selective serotonin reuptake inhibitors such as paroxetine and citalopram; venlafaxine, bupropion). Anti-seizure medications (e.g., carbamazepine, phenytoin, gabapentin, pregabalin, lamotrigine) can also be effective treatments for neuropathic pain.

[0015] Neuropathic pain can respond to opioid analgesics such as tramadol hydrochloride, morphine, and oxycodone hydrochloride.

[0016] Patients with localized pain who are unable to take oral medications can benefit from localized regional anesthetic preparations such as lidocaine and capsaicin, often in patch or gel / cream form.

[0017] Neuromodulation by spinal cord stimulation may be effective in some patients. Many patients with chronic neuropathic pain require multidisciplinary management, including physical therapy and psychological support.

[0018] (A novel treatment for neuropathic pain (NP)) Applicants have previously shown that various bicycloheteroaryl-heteroaryl-benzoic acid compounds act as retinoic acid receptor beta (RARβ) agonists and induce axonal outgrowth in models of nerve injury. See, e.g., Borthwick et al., 2016.

[0019] For nerve cells to communicate with each other, these cells need to form synapses. However, other studies using other axonal extension molecules or interventions have not provided evidence that accurate synaptic connections will be formed. Thus, treatment with compounds that induce axonal extension (e.g., the treatment described in Borthwick et al., 2016) is expected to result in synapses that are formed in a fortuitous manner and have misconnections. It is these misconnections that cause pain. Pain may result from inflammatory cells in the brain, such as microglia and astrocytes, which regulate the structure and function of synapses.

[0020] Applicants have now surprisingly and unexpectedly shown that certain compounds that induce axonal outgrowth (described in Borthwick et al., 2016) can be used to treat and prevent neuropathic pain, and may do so by downregulating inflammatory pathways.

[0021] As described herein, BOBA-001 prevents neuropathic pain in rats; BOBA-001 modulates thermal and mechanical thresholds and downregulates key inflammatory and pain mediators.

[0022] Thus, BOBA-001, as well as the other BOBA compounds described herein, are likely to be useful for the treatment and prevention of neuropathic pain, which is surprising and unexpected because BOBA-001, as well as the other BOBA compounds described herein, also induce axonal outgrowth.

[0023] (Known compound) Borthwick et al., 2016, describe certain bicycloheteroaryl-heteroaryl-benzoic acid (BHBA) compounds, their activity in (selective) activation of RARβ2 (e.g., RARβ2), and their use in treating diseases and conditions mediated by RARβ (e.g., RARβ2), including neuronal injury such as spinal cord injury. Among the examples provided in their publication are certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds designated "BHBA-001" through "BHBA-020."

[0024] Borthwick et al., 2017, describe the preparation and characterization of a specific crystalline form of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid, referred to therein as "BHBA-001."

[0025] Chiang et al., 2008, claims that neuropathic pain can be treated by retinoic acid receptor (RAR) agonists (not specified as to which subtype, e.g., RARα, RARβ, etc.). The document merely refers to two classes of compounds (one based on tazarotene and one based on R-667), which have undergone clinical trial studies (for the treatment of psoriasis and emphysema, respectively). The document claims that these compounds can also be used to treat pain, including neuropathic pain. The document does not provide supporting data, but rather refers to studies that have not yet been performed (see, e.g., page 14, lines 11-12 of the document; "The activity of R-667 and tazarotene will be demonstrated in the SNL model with the following protocol"). Summary of the Invention

[0026] Summary of the Invention The present invention relates to certain substituted 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid compounds (collectively referred to herein as BOBA compounds) as described herein, and pharmaceutical compositions comprising such compounds, useful for the treatment or prevention of neuropathic pain as described herein.

[0027] One aspect of the present invention pertains to a BOBA compound, as described herein, or a pharmaceutical composition comprising a BOBA compound, as described herein, for use in a method for the treatment or prevention of neuropathic pain.

[0028] Another aspect of the present invention relates to the use of a BOBA compound, as described herein, in the manufacture of a medicament for the treatment or prevention of neuropathic pain.

[0029] Another aspect of the present invention relates to a method for treating or preventing neuropathic pain, comprising administering to a patient in need of such treatment a therapeutically effective amount of a BOBA compound described herein, or a pharmaceutical composition comprising a BOBA compound described herein.

[0030] Another aspect of the present invention relates to the use of a BOBA compound as described herein, or a pharmaceutical composition comprising a BOBA compound as described herein, in the treatment or prevention of neuropathic pain.

[0031] Another aspect of the present invention relates to a kit comprising: (a) a BOBA compound as described herein, or a composition comprising a BOBA compound as described herein, e.g., preferably provided in a suitable container and / or with suitable packaging; and (b) instructions for use, e.g., written instructions on how to administer the compound or composition for the treatment or prevention of neuropathic pain.

[0032] In one embodiment, the BOBA compounds or pharmaceutical compositions comprising the BOBA compounds are administered orally, e.g., by orally administering an oral medication, etc.

[0033] As will be appreciated by those skilled in the art, features and preferred embodiments of one aspect of the invention also relate to other aspects of the invention. [Brief description of the drawings]

[0034] [Figure 1] Graph of mechanical paw withdrawal threshold (grams) versus time (days) after surgery for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo treatment, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001. [Diagram 2] Graph of hot plate paw withdrawal (seconds) versus time (days) after surgery for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo treatment, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals (n=8) per group; 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001. [Diagram 3] Graph of cold plate paw withdrawal (seconds) versus time (days) after surgery for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals (n=8) per group; 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001. [Figure 4]Graph of Randall Sellito paw withdrawal threshold (grams) versus time after surgery (days) for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001. [Diagram 5] Bar graph showing TNFα:GAPDH expression ratio in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Three animals per group (n=3). Data are reported as mean ± standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001. [Figure 6] Bar graph showing TNFR1:GAPDH expression ratio in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Three animals per group (n=3). Data are reported as mean±standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001. [Figure 7] Bar graphs showing BDNF levels (arbitrary units) in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Five serial sections per injured spinal cord analyzed from three animals per group (n=3). Data are reported as mean ± standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0035] Detailed Description of the Invention compound The present invention relates to certain compounds, and pharmaceutical compositions containing those compounds, useful for the treatment or prevention of neuropathic pain as described herein.

[0036] The compound is 4-[5-(benzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid, shown below:

[0037] [ka] Regarding.

[0038] Therefore, the compound has -R Q1 , -R Q2 , -R Q3 , -R Q4 , -R Q5 , -R P1 , -R P2 , -and, -R A and pharma- ceutically acceptable salts, hydrates, and solvates thereof (for convenience, collectively referred to herein as "benzofuranyl-oxadiazolyl-benzoic acid compounds" or "BOBA compounds"), wherein

[0039] [ka]

[0040] In some embodiments of the present invention, the compound is defined as follows:

[0041] (1) A compound of the following formula, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof:

[0042] [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C is -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -RQ5C and; -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHRP2DD , or -NR P2DD 2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 It is alkyl, phenyl, or benzyl.

[0043] The term "saturated linear or branched chain C 1-3 "Alkyl" means -CH3 (methyl, -Me), -CH2CH3 (ethyl, -Et), -CH2CH2CH3 (n-propyl, -nPr), and -CH(CH3)2 (iso-propyl, -iPr).

[0044] The term "saturated linear or branched chain C 1-4 "Alkyl" further includes -CH2CH2CH2CH3(n-butyl, -nBu), -CH2CH(CH3)2(iso-butyl, -iBu), -CH(CH3)CH2CH3(sec-butyl, -sBu), and -CH(CH3)3(tert-butyl, -tBu).

[0045] For the avoidance of doubt, -R Q1 , -R Q2 , -R Q3 , -R Q4 , -R Q5 , -R P1 , R P2 , and -R A It is not intended that any two or more of -R be taken together to form a ring fused to the ring(s) to which they are attached. For example, -R P1 and -R P2 are not intended to be taken together to form a ring fused to the ring to which they are attached. Q1 and -R Q3 are not intended to be taken together to form a ring fused to the ring to which they are attached.

[0046] Group-R Q1 (2) -R Q1 -R Q1A The compound according to (1). (3) -R Q1 -R Q1B The compound according to (1). (4) -R Q1 -R Q1C The compound according to (1).

[0047] Group-R Q2 (5) -R Q2 -R Q2A The compound according to any one of (1) to (4), (6) -R Q2 -R Q2B The compound according to any one of (1) to (4), (7) -R Q2 -R Q2C The compound according to any one of (1) to (4),

[0048] Group-R Q3 (8) -R Q3 A compound according to any one of (1) to (7), wherein is -H. (9) -R Q3 -R Q3A The compound according to any one of (1) to (7), (10) -R Q3 -R Q3B The compound according to any one of (1) to (7), (11) -R Q3 -R Q3C The compound according to any one of (1) to (7),

[0049] Group-R Q4 (12) -R Q4 A compound according to any one of (1) to (11), wherein (13) -R Q4 -R Q4AThe compound according to any one of (1) to (11), (14) -R Q4 -R Q4B The compound according to any one of (1) to (11), (15) -R Q4 -R Q4C The compound according to any one of (1) to (11),

[0050] Group-R Q5 (16) -R Q5 A compound according to any one of (1) to (15), wherein: (17) -R Q5 -R Q5A The compound according to any one of (1) to (15), (18) -R Q5 -R Q5B The compound according to any one of (1) to (15), (19) -R Q5 -R Q5C The compound according to any one of (1) to (15),

[0051] Group-R Q1A (20) -R Q1A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (19), wherein the compound is alkyl. (21) -R Q1A A compound according to any one of (1) to (19), wherein, if present, is -Me.

[0052] Group-R Q2A (22) -R Q2A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (21), wherein the compound is alkyl. (23) -R Q2A A compound according to any one of (1) to (21), wherein, if present, is -Me.

[0053] Group-R Q3A (24) -R Q3A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (23), wherein the compound is alkyl. (25) -R Q3A A compound according to any one of (1) to (23), wherein, if present, is -Me.

[0054] Group-R Q4A (26) -R Q4A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (25), wherein the compound is alkyl. (27) -R Q4A A compound according to any one of (1) to (25), wherein, if present, is -Me.

[0055] Group-R Q5A (28) -R Q5A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (27), wherein the compound is alkyl. (29) -R Q5A A compound according to any one of (1) to (27), wherein, if present, is -Me.

[0056] Group-R Q1B (30) -R Q1B A compound according to any one of (1) to (29), wherein, if present, is independently -F or -Cl. (31) -R Q1B A compound according to any one of (1) to (29), wherein, if present, is -F. (32) -R Q1B A compound according to any one of (1) to (29), wherein, if present, is -Cl.

[0057] Group-R Q2B (33) -R Q2BA compound according to any one of (1) to (32), wherein, if present, is independently -F or -Cl. (34) -R Q2B A compound according to any one of (1) to (32), wherein, if present, is -F. (35) -R Q2B A compound according to any one of (1) to (32), wherein, if present, is -Cl.

[0058] Group-R Q3B (36) -R Q3B A compound according to any one of (1) to (35), wherein, if present, is independently -F or -Cl. (37) -R Q3B A compound according to any one of (1) to (35), wherein, if present, is -F. (38) -R Q3B A compound according to any one of (1) to (35), wherein, if present, is -Cl.

[0059] Group-R Q4B (39) -R Q4B A compound according to any one of (1) to (38), wherein, if present, is independently -F or -Cl. (40) -R Q4B A compound according to any one of (1) to (38), wherein, if present, is -F. (41) -R Q4B A compound according to any one of (1) to (38), wherein, if present, is -Cl.

[0060] Group-R Q5B (42) -R Q5B A compound according to any one of (1) to (42), wherein, if present, is independently -F or -Cl. (43) -R Q5B A compound according to any one of (1) to (42), wherein, if present, is -F. (44) -R Q5BA compound according to any one of (1) to (42), wherein, if present, is -Cl.

[0061] Group-R P1 (45) -R P1 A compound according to any one of (1) to (44), wherein (46) -R P1 -R P1X The compound according to any one of (1) to (44):

[0062] Group-R P2 (47) -R P2 A compound according to any one of (1) to (46), wherein is -H. (48) -R P2 -R P2X The compound according to any one of (1) to (46),

[0063] Group-R P1X (49) -R P1X If present, it is independent of -R P1A , -R P1B , or -R P1C The compound according to any one of (1) to (48), (50) -R P1X If present, -R P1A The compound according to any one of (1) to (48), (51) -R P1X If present, -R P1B The compound according to any one of (1) to (48), (52) -R P1X If present, -R P1C The compound according to any one of (1) to (48),

[0064] Group-R P2X (53) -R P2X If present, it is independent of -R P2A , -R P2B , or -R P2CThe compound according to any one of (1) to (52), (54) -R P2X If present, -R P2A The compound according to any one of (1) to (52), (55) -R P2X If present, -R P2B The compound according to any one of (1) to (52), (56) -R P2X If present, -R P2C The compound according to any one of (1) to (52),

[0065] Group-R P1A (57) -R P1A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (56), wherein the compound is alkyl. (58) -R P1A A compound according to any one of (1) to (56), wherein, if present, is -Me.

[0066] Group-R P2A (59) -R P2A If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (58), wherein the compound is alkyl. (60) -R P2A A compound according to any one of (1) to (58), wherein, if present, is -Me.

[0067] Group-R P1B (61) -R P1B A compound according to any one of (1) to (60), wherein, if present, is independently -F, -Cl, or -Br. (62) -R P1B A compound according to any one of (1) to (60), wherein, if present, is independently -F or -Cl. (63) -R P1BA compound according to any one of (1) to (60), wherein, if present, is -F. (64) -R P1B A compound according to any one of (1) to (60), wherein, if present, is -Cl.

[0068] Group-R P2B (65) -R P2B A compound according to any one of (1) to (64), wherein, if present, is independently -F, -Cl, or -Br. (66) -R P2B A compound according to any one of (1) to (64), wherein, if present, is independently -F or -Cl. (67) -R P2B A compound according to any one of (1) to (64), wherein, if present, is -F. (68) -R P2B A compound according to any one of (1) to (64), wherein, if present, is -Cl.

[0069] Group-R P1D (69) -R P1D A compound according to any one of (1) to (68), wherein, if present, is -NH2.

[0070] Group-R P2D (70) -R P2D A compound according to any one of (1) to (69), wherein, if present, is -NH2.

[0071] Group-R P1DD (71) -R P1DD If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (70), wherein the compound is alkyl. (72) -R P1DD A compound according to any one of (1) to (70), wherein, if present, is -Me.

[0072] Group-R P2DD (73) -R P2DD If present, saturated linear or branched chain C 1-3 A compound according to any one of (1) to (72), wherein the compound is alkyl. (74) -R P2DD A compound according to any one of (1) to (72), wherein, if present, is -Me.

[0073] Group-R A (75) -R A A compound according to any one of (1) to (74), wherein is -H. (76) -R A -R AA The compound according to any one of (1) to (74),

[0074] Group-R AA (77) -R AA If present, saturated linear or branched chain C 1-4 A compound according to any one of (1) to (76), wherein the compound is alkyl.

[0075] (Some preferred compounds) (78) The compound according to (1), which is a compound represented by one of the following formulas, or a pharma- ceutically acceptable salt, hydrate or solvate thereof:

[0076] [Table 1] TIFF0007595033000005.tif228145TIFF0007595033000006.tif222145TIFF0007595033000007.tif72145

[0077] (79) The compound according to (1), which is a compound of the following formula, or a pharma- ceutically acceptable salt, hydrate or solvate thereof:

[0078] [Table 2]

[0079] (combination) It will be understood that certain features of the invention that are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination. Q1 , -R Q1A , -R Q1B , -R Q1C , -R Q2 , -R Q2A , -R Q2B , -R Q2C , -R Q3 , -R Q3A , -R Q3B , -R Q3C , -R Q4 , -R Q4A , -R Q4B , -R Q4C , -R Q5 , -R Q5A , -R Q5B , -R Q5C , -R P1 , -R P1X , -R P1A , -R P1B , -R P1C , -R P1D , -R P2 , -R P2X , -R P2A , -R P2B , -R P2C , -R P2D , -R A , -R AAAll combinations of the embodiments with respect to chemical groups represented by the above symbols (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 112, 120, 132, 140, 150, 162, 170, 181, 192, 193, 194, 195, 196, 197, 198, 199, 102, 103, 1

[0080] (Substantially Purified Form) In some embodiments of the present invention, the BOBA compounds described herein are used in a substantially purified and / or substantially free of contaminants.

[0081] In one embodiment, the compound is in a substantially purified form having a purity of at least 50% by weight, such as at least 60% by weight, such as at least 70% by weight, such as at least 80% by weight, such as at least 90% by weight, such as at least 95% by weight, such as at least 97% by weight, such as at least 98% by weight, such as at least 99% by weight.

[0082] In one embodiment the compound is in a form that is substantially free of contaminants, the contaminants being 50% by weight or less, such as 40% by weight or less, for example 30% by weight or less, such as 20% by weight or less, for example 10% by weight or less, such as 5% by weight or less, for example 3% by weight or less, such as 2% by weight or less, for example 1% by weight or less.

[0083] (Isomers) Certain compounds may exist in one or more particular geometric isomeric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, such as, but not limited to, cis- and trans-forms, E- and Z-forms, c-, t- and r-forms, endo- and exo-forms, R-, S- and meso-forms, D- and L-forms, d- and l-forms, (+)- and (-)-forms, keto-, enol- and enolate-forms, syn- and anti-forms, synclinal and anticlinal forms, α- and β-forms, axial and equatorial forms, boat-, chair-, twisted-, envelope-, and half-chair-forms, and combinations thereof (collectively referred to hereinafter as "isomers" (or "isomeric forms").

[0084] It should be noted that, except as discussed below regarding tautomeric forms, the term "isomer" as used herein specifically excludes structural (or constitutional) isomers (i.e., isomers that differ with respect to the bonds between the atoms, and not simply the position of the atoms in space). For example, a reference to a methoxy group (-OCH3) is not to be construed as a reference to its structural isomer, the hydroxymethyl group (-CH2OH). However, a reference to a class of structures may well include structurally isomeric forms within that class (e.g., C 1-4 Alkyl includes n-propyl and iso-propyl, and butyl includes n-, iso-, sec-, and tert-butyl).

[0085] The above exclusion does not relate to tautomeric forms, such as keto, enol, and enolate forms, as in, for example, the following tautomeric pairs: keto / enol (exemplified below), imine / enamine, amide / iminoalcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, N-nitroso / hydroxyazo, and nitro / aci-nitro.

[0086] [ka]

[0087] It should be noted that specifically included within the term "isomer" are compounds with one or more isotopic substitutions. For example, H is 1 H, 2 H(D) and 3 H(T), or any isotopic form; C is 12 C. 13 C, and 14 C may be in any isotopic form; 16 O and 18 It may be in any isotopic form, such as O.

[0088] Unless otherwise specified, a reference to a particular compound encompasses all such isomeric forms, including mixtures thereof.

[0089] (salt) It may be convenient or desirable to prepare, purify, and / or handle corresponding salts of the above compounds, e.g., pharma- ceutically acceptable salts. Examples of pharma-ceutically acceptable salts are discussed in Berge et al., 1977, "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-19.

[0090] For example, if the compound is anionic, or has a functional group that can be anionic (e.g., -COOH can be replaced with -COO - Examples of suitable inorganic cations include, but are not limited to, Na + and K + Alkali metal ions such as Ca 2+ and Mg 2+ Alkaline earth cations such as Al 3+ Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH + ) and substituted ammonium ions (e.g., NHR +, NH2R2 + , NHR3 + , NR4 + Some suitable examples of substituted ammonium ions include ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as those derived from amino acids such as lysine and arginine. One common example of a quaternary ammonium ion is N(CH3)4 + It is.

[0091] If the compound is cationic or has a functional group that can be cationic (e.g., -NH2 can be converted to -NH3 + The anions may form salts with suitable anions. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfurous acid, nitric acid, nitrous acid, phosphoric acid, and phosphorous acid.

[0092] Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetyloxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, 1,2-ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalenecarboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric acid. Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose, and the like.

[0093] Unless otherwise specified, a reference to a particular compound also includes its salt forms.

[0094] (Hydrates and solvates) It may be convenient or desirable to prepare, purify, and / or handle the corresponding solvates of the compounds. The term "solvate" is used herein in the conventional sense to refer to a complex of a solute (e.g., a compound, a salt of a compound) and a solvent. When the solvent is water, the solvate may be conveniently referred to as a hydrate (e.g., a monohydrate, a dihydrate, a trihydrate, etc.).

[0095] Unless otherwise specified, a reference to a particular compound also encompasses solvated and hydrated forms thereof.

[0096] (chemically protected form) It may be convenient or desirable to prepare, purify, and / or handle compounds in a chemically protected form. The term "chemically protected form" is used herein in its conventional chemical sense to refer to compounds in which one or more reactive functional groups are protected from undesired chemical reactions under certain conditions (e.g., pH, temperature, radiation, solvents, etc.). Indeed, well-known chemical methods are used to reversibly render otherwise reactive functional groups unreactive under certain conditions. In a chemically protected form, one or more reactive functional groups are in the form of protected or protective groups (also known as masked or masking groups, or blocked or blocking groups). By protecting reactive functional groups, reactions involving other unprotected reactive functional groups can be carried out without affecting the protected groups, and the protecting groups can usually be removed in a subsequent step without substantially affecting the remainder of the molecule. See, for example, Protective Groups in Organic Synthesis (T. Greene and P. Wuts; 4th ed.; John Wiley and Sons, 2006).

[0097] A variety of such "protecting," "blocking," or "masking" methods are widely used and well known in organic synthesis. For example, a compound having two unequal reactive functional groups, both of which may be reactive under certain conditions, can be derivatized such that one of the functional groups is "protected" and therefore non-reactive under certain conditions, and the compound so protected can be used as a reactant that effectively has only one reactive functional group. After the desired reaction (involving the other functional group) is complete, the protected group can be "deprotected" to return it to its original functionality.

[0098] For example, amine groups may be represented as, for example, amides (-NRCO-R) or urethanes (-NRCO-OR), for example, as methylamides (-NHCO-CH3); as benzyloxyamides (-NHCO-OCH2C6H5, -NH-Cbz); as t-butoxyamides (-NHCO-OC(CH3)3, -NH-Boc). It may be protected as 2-biphenyl-2-propoxyamide (-NHCO-OC(CH3)2C6H4C6H5, -NH-Bpoc), 9-fluorenylmethoxyamide (-NH-Fmoc), 6-nitroveratryloxyamide (-NH-Nvoc), 2-trimethylsilylethyloxyamide (-NH-Teoc), 2,2,2-trichloroethyloxyamide (-NH-Troc), allyloxyamide (-NH-Alloc), 2(-phenylsulfonyl)ethyloxyamide (-NH-Psec) or, where appropriate (e.g. cyclic amines), as a nitroxide radical (>NO·).

[0099] For example, a carboxylic acid group can be reacted as an ester, e.g., C 1-6 Alkyl esters (e.g., methyl esters; t-butyl esters); C 1-6 Haloalkyl esters (e.g., C 1-6 Trihaloalkyl esters); TriC 1-6 Alkylsilyl-C 1-7 Alkyl ester; or C 5-20 Aryl-C1-6 It may be protected as an alkyl ester (eg benzyl ester; nitrobenzyl ester); or as an amide, eg methyl amide.

[0100] (Prodrug) It may be convenient or desirable to prepare, purify, and / or handle a compound in the form of a prodrug. As used herein, the term "prodrug" refers to a compound that, when metabolized (e.g., in vivo), yields the desired active compound. Typically, prodrugs are inactive or less active than the desired active compound, but may offer advantageous handling, administration, or metabolic properties.

[0101] For example, some prodrugs are esters of active compounds (e.g., physiologically acceptable metabolically labile esters). During metabolism, the ester group (-C(=O)OR) is cleaved to produce the active drug. Such esters can be formed, for example, by esterification with any of the carboxylic acid groups (-C(=O)OH) in the parent compound, and, if appropriate, with any other reactive groups present in the parent compound before protection, followed by deprotection if necessary.

[0102] Again, some prodrugs are enzymatically activated to yield the active compound, or to yield a compound that upon further chemical reaction yields the active compound (e.g., as in ADEPT, GDEPT, LIDEPT, etc.) For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.

[0103] (General Chemical Synthesis) Methods for the chemical synthesis of BOBA compounds as described herein can be found, for example, in Borthwick et al, 2016, the contents of which are incorporated herein by reference. See in particular pages 35-48 (general methods) and 63-94 (exemplary methods) therein. Additional methods for the chemical synthesis of BOBA-001 as described herein can be found, for example, in Borthwick et al, 2017, the contents of which are incorporated herein by reference. See in particular pages 21-28 therein. These and / or other known methods can be modified and / or adapted in known manners to facilitate the synthesis of additional BOBA compounds.

[0104] Pharmaceutical Composition The pharmaceutical compositions described herein are useful for the treatment or prevention of neuropathic pain.

[0105] The pharmaceutical composition comprises a BOBA compound described herein and a pharma- ceutically acceptable carrier, diluent, or excipient.

[0106] In one embodiment, the pharmaceutical composition further comprises one or more additional therapeutic agents.

[0107] (use) The BOBA compounds described herein, and pharmaceutical compositions comprising the BOBA compounds described herein, are useful in the treatment or prevention of neuropathic pain, as described herein.

[0108] One aspect of the present invention pertains to a BOBA compound, as described herein, or a pharmaceutical composition comprising a BOBA compound, as described herein, for use in a method for the treatment or prevention of neuropathic pain.

[0109] Another aspect of the present invention relates to the use of a BOBA compound as described herein in the manufacture of a medicament for the treatment or prevention of neuropathic pain. In one embodiment, the medicament comprises a BOBA compound.

[0110] Another aspect of the present invention relates to a method for treating or preventing neuropathic pain, comprising administering to a patient in need of such treatment a therapeutically effective amount of a BOBA compound described herein, or a pharmaceutical composition comprising a BOBA compound described herein.

[0111] Another aspect of the present invention relates to the use of a BOBA compound as described herein, or a pharmaceutical composition comprising a BOBA compound as described herein, in the treatment or prevention of neuropathic pain.

[0112] (Neuropathic pain) The present invention relates to certain compounds, and pharmaceutical compositions containing those compounds, useful for the treatment or prevention of neuropathic pain as described herein.

[0113] As mentioned above, neuropathic pain is a chronic condition caused by lesions or pathological changes in the nervous system. Neuropathic pain frequently and often rapidly appears after nerve injury and spinal cord injury, and in certain diseases, causes debilitation and reduced quality of life for patients.

[0114] Neuropathic pain arises from inflammation of cells in the nervous system, which leads to synapse loss and / or the formation of misconnections in remaining nerve cells.The BOBA compounds described herein (a) can cause axonal growth, thus correcting synaptic connections, and (b) have anti-inflammatory effects.Therefore, as shown herein, the compounds can be used to treat and prevent neuropathic pain.

[0115] In one embodiment, the neuropathic pain is peripheral neuropathic pain.

[0116] In one embodiment, the neuropathic pain is central neuropathic pain.

[0117] In one embodiment, the neuropathic pain is chronic neuropathic pain.

[0118] In one embodiment, the neuropathic pain is intractable neuropathic pain.

[0119] In one embodiment, the neuropathic pain is neuropathic pain associated with metabolic dysfunction, such as diabetes and pre-diabetes.

[0120] In one embodiment, the neuropathic pain is diabetes associated neuropathic pain.

[0121] In one embodiment, the neuropathic pain is neuropathic pain associated with pre-diabetes.

[0122] In one embodiment, the neuropathic pain is neuropathic pain associated with painful polyneuropathy.

[0123] In one embodiment, the neuropathic pain is neuropathic pain associated with painful diabetic neuropathy, such as diabetic peripheral neuropathy.

[0124] In one embodiment, the neuropathic pain is neuropathic pain associated with painful diabetic polyneuropathy.

[0125] In one embodiment, the neuropathic pain is neuropathic pain associated with post-herpetic neuralgia.

[0126] In one embodiment, the neuropathic pain is neuropathic pain associated with trigeminal neuralgia.

[0127] In one embodiment, the neuropathic pain is neuropathic pain associated with occipital neuralgia.

[0128] In one embodiment, the neuropathic pain is neuropathic pain associated with painful radiculopathy, such as lumbar and cervical painful radiculopathy.

[0129] In one embodiment, the neuropathic pain is neuropathic pain associated with infectious diseases such as herpes zoster (shingles), HIV infection, Lyme disease, diphtheria, and leprosy.

[0130] In one embodiment, the neuropathic pain is neuropathic pain associated with liver or kidney damage, such as chronic liver or kidney damage, such as liver disease, liver failure, kidney disease, and kidney failure.

[0131] In one embodiment, the neuropathic pain is neuropathic pain associated with an immune or inflammatory disorder, such as Guillain-Barre syndrome, rheumatoid arthritis, lupus, Sjogren's syndrome, and celiac disease.

[0132] In one embodiment, the neuropathic pain is neuropathic pain associated with an inherited neuropathic disorder or channelopathy, such as hereditary erythromelalgia, paroxysmal acute pain syndrome, and Charcot-Marie-Tooth disease (CMT).

[0133] In one embodiment, the neuropathic pain is neuropathic pain associated with small fiber sensory neuropathy.

[0134] In one embodiment, the neuropathic pain is neuropathic pain associated with a thyroid hormone disorder, such as hypothyroidism.

[0135] In one embodiment, the neuropathic pain is neuropathic pain associated with stroke.

[0136] In one embodiment, the neuropathic pain is neuropathic pain associated with cancer, such as lymphoma and multiple myeloma.

[0137] In one embodiment, the neuropathic pain is neuropathic pain associated with chemotherapy, for example cancer chemotherapy.

[0138] In one embodiment, the neuropathic pain is neuropathic pain associated with peripheral nerve injury pain.

[0139] In one embodiment, the neuropathic pain is neuropathic pain associated with post-traumatic nerve damage.

[0140] In one embodiment, the neuropathic pain is neuropathic pain associated with post-traumatic neuropathy.

[0141] In one embodiment, the neuropathic pain is neuropathic pain associated with spinal cord injury, such as trauma, such as spinal cord injury caused by a traffic accident.

[0142] In one embodiment, the neuropathic pain is neuropathic pain associated with traumatic peripheral nerve injury.

[0143] In one embodiment, the neuropathic pain is neuropathic pain associated with post-surgical neuropathy (eg, post-surgical neuropathic pain).

[0144] In one embodiment, the neuropathic pain is post-surgical neuropathic pain, such as neuropathic pain following neurosurgery (such as spinal surgery).

[0145] In one embodiment, the neuropathic pain is neuropathic pain associated with fibromyalgia.

[0146] In one embodiment, the neuropathic pain is neuropathic pain associated with lower back pain.

[0147] In one embodiment, the neuropathic pain is neuropathic pain associated with carpal tunnel syndrome.

[0148] In one embodiment, the neuropathic pain is neuropathic pain associated with burning pain.

[0149] In one embodiment, the neuropathic pain is neuropathic pain associated with reflex sympathetic dystrophy (RSD).

[0150] In one embodiment, the neuropathic pain is neuropathic pain associated with complex regional pain syndrome (CRPS), such as types 1 and 2.

[0151] In one embodiment, the neuropathic pain is neuropathic pain associated with amputation.

[0152] In one embodiment, the neuropathic pain is neuropathic pain associated with a neurodegenerative disease, such as Parkinson's disease.

[0153] In one embodiment, the neuropathic pain is neuropathic pain associated with stroke, such as central post-stroke pain.

[0154] In one embodiment, the neuropathic pain is neuropathic pain associated with syringomyelia.

[0155] In one embodiment, the neuropathic pain is neuropathic pain associated with demyelinating diseases such as multiple sclerosis, transverse myelitis, and neuromyelitis optica.

[0156] In one embodiment, the neuropathic pain is idiopathic neuropathic pain.

[0157] (Treatment and Prevention) As noted above, the present invention relates to certain compounds, and pharmaceutical compositions containing those compounds, that are useful for the treatment or prevention of neuropathic pain as described herein.

[0158] The compounds can be administered, for example, at the time of nerve injury or shortly after nerve injury (e.g., after a traffic accident, spinal cord surgery, etc.) to prevent or alleviate the onset of neuropathic pain. Alternatively, the compounds may be administered when neuropathic pain is detected, for example during the course of a disease (e.g., diabetic neuropathy) or during recovery from nerve injury or surgery.

[0159] The term "treatment or prevention" as used herein in the context of treatment or prevention of a condition generally relates to treatment and therapy, whether for humans or animals (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, such as inhibition of progression of the condition and, for example, reducing the rate of progression, halting the rate of progression, alleviating the symptoms of the condition, ameliorating the condition, and curing the condition. Treatment as a preventative measure (i.e., prophylaxis) is also encompassed, such as use by patients who do not develop the condition, but who are at risk of developing the condition.

[0160] For example, treatment or prevention of neuropathic pain includes: preventing the onset of neuropathic pain, inhibiting the progression of neuropathic pain, reducing the rate of progression of neuropathic pain, reducing the incidence of neuropathic pain, reducing the severity of neuropathic pain, reducing one or more symptoms of neuropathic pain, ameliorating neuropathic pain, curing neuropathic pain, and the like.

[0161] The term "therapeutically effective amount" as used herein relates to an amount of a compound, or a material, composition or dosage form containing a compound, that is effective to produce some desired therapeutic effect when administered in accordance with a desired treatment regimen, commensurate with a reasonable benefit / risk ratio.

[0162] (kit) One aspect of the present invention relates to a kit comprising (a) a BOBA compound as described herein, or a composition comprising a BOBA compound as described herein, preferably provided, e.g., in a suitable container and / or with suitable packaging, and (b) instructions for use, e.g., written instructions on how to administer the compound or composition, for the treatment or prevention of neuropathic pain.

[0163] (Route of Administration) The BOBA compounds, or pharmaceutical compositions containing the BOBA compounds, may be administered to a subject by any convenient route of administration, whether systemic / peripheral or local (i.e., at the desired site of action).

[0164] Routes of administration include oral (e.g., by ingestion); buccal administration; sublingual administration; transdermal administration (e.g., by patch, plaster, etc.); transmucosal administration (e.g., by patch, plaster, etc.); intranasal administration (e.g., by nasal spray, nasal drops, or from a nebulizer or dry powder delivery device), ocular administration (e.g., by eye drops), pulmonary administration (e.g., by inhalation or insufflation therapy using an aerosol, e.g., through the mouth or nose), rectal administration (e.g., by suppository administration by injection, such as by a catheter or enema), vaginal administration (e.g., by a pessary); parenteral administration, such as by injection, e.g., subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal injection; administration, e.g., by subcutaneous or intramuscular depot or reservoir implantation.

[0165] In one preferred embodiment, the route of administration is oral (eg, by ingestion).

[0166] (Subjects / Patients) The subject / patient may be a chordate, vertebrate, mammal, placental mammal, marsupial (e.g., kangaroo, wombat), rodent (e.g., guinea pig, hamster, rat, mouse), murine (e.g., mouse), lagomorph (e.g., rabbit), avian (e.g., bird), canine (e.g., dog), feline (e.g., cat), equine (e.g., horse), porcine (e.g., pig), ovine (e.g., sheep), bovine (e.g., cow), primate, simian (e.g., monkey or ape), monkey (e.g., marmoset, baboon), ape (e.g., gorilla, chimpanzee, orangutan, gibbon), or human. Additionally, the subject / patient may be in any of its forms of development, for example, a fetus.

[0167] In one preferred embodiment, the subject / patient is a human.

[0168] (formulation) While it is possible for a BOBA compound to be administered alone, it is preferred to provide at least one BOBA compound described herein as a pharmaceutical composition (e.g., formulation, preparation, medicament) comprising at least one of the BOBA compounds described herein in combination with one or more other pharma- ceutically acceptable components well known to those skilled in the art, such as, for example, pharma- ceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavorants, and sweeteners. The composition may further comprise other active agents, such as other therapeutic or prophylactic agents.

[0169] Also provided is a method for preparing a pharmaceutical composition comprising mixing at least one BOBA compound described herein with one or more other pharma- ceutically acceptable ingredients known to those of skill in the art, such as carriers, diluents, excipients, etc. When formulated as separate units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the compound.

[0170] As used herein, the term "pharmaceutical acceptable" refers to compounds, components, materials, compositions, dosage forms, etc., that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of a subject (e.g., a human) that is compatible with a reasonable benefit-risk ratio without excessive toxicity, irritation, allergic response, or other problem or complication. Each carrier, diluent, excipient, etc. must also be "acceptable" in the sense of being compatible with the other ingredients of the formulation.

[0171] Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical textbooks, such as Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, Pa., 1990; and Handbook of Pharmaceutical Excipients, 5th Edition, 2005.

[0172] The formulation can be prepared by any method known in the pharmaceutical art. Such method includes the step of bringing the compound into association with a carrier, which constitutes one or more accessory ingredients. In general, the formulation is prepared by uniformly and intimately bringing the compound into association with a carrier (e.g., liquid carrier, finely divided solid carrier, etc.), and then, if necessary, shaping the product.

[0173] The formulations can be prepared to provide rapid or slow release, immediate, delayed, timed, or sustained release, or any combination thereof.

[0174] The formulation may suitably be in the form of a liquid, a solution (e.g., aqueous, non-aqueous), a suspension (e.g., aqueous suspension, non-aqueous suspension), an emulsion (e.g., oil-in-water, water-in-oil), an elixir, a syrup, a electuary, a mouthwash, a drop, a tablet (e.g., coated tablets, etc.), a granule, a powder, a lozenge, a troche, a capsule (e.g., hard gelatin capsules and soft gelatin capsules, etc.), a cachet, a pill, an ampoule, a bolus, a suppository, a pessary, a tincture, a gel, a paste, an ointment, a cream, a lotion, an oil, a foam, a spray, a mist, or an aerosol.

[0175] Formulations may suitably be presented as a patch, bandage, dressing, or the like impregnated with one or more compounds and optionally one or more other pharma- ceutically acceptable ingredients, such as penetration enhancers, permeation enhancers, and absorption enhancers. Formulations may also suitably be presented in the form of a depot or reservoir.

[0176] The compound may be dissolved in, suspended in, or mixed with one or more other pharma- ceutical acceptable components. The compound may be provided in a liposome or other microparticle designed to target the compound, for example, to blood components or one or more organs.

[0177] Formulations suitable for oral administration (e.g., by ingestion) include liquids, solutions (e.g., aqueous and non-aqueous solutions), suspensions (e.g., aqueous suspensions and non-aqueous suspensions), emulsions (e.g., oil-in-water and water-in-oil), elixirs, syrups, lozenges, tablets, granules, powders, capsules, cachets, pills, ampoules, boluses, and the like.

[0178] Formulations suitable for buccal administration include mouthwashes, lozenges, pastilles, as well as patches, bandages, depots, and reservoirs.Lozenges typically contain the compound in a flavored base, usually sucrose and acacia or tragacanth.Pastryces typically contain the compound in an inert matrix, such as gelatin and glycerin, or sucrose and acacia.Mouthwashes typically contain the compound in a suitable liquid carrier.

[0179] Formulations suitable for sublingual administration include tablets, lozenges, troches, capsules, and pills.

[0180] Formulations suitable for oral transmucosal administration include liquids, solutions (e.g., aqueous and non-aqueous solutions), suspensions (e.g., aqueous and non-aqueous suspensions), emulsions (e.g., oil-in-water and water-in-oil), mouthwashes, lozenges, troches, as well as patches, bandages, depots, and reservoirs.

[0181] Formulations suitable for parenteral transmucosal administration include liquids, solutions (e.g., aqueous and non-aqueous solutions), suspensions (e.g., aqueous and non-aqueous suspensions), emulsions (e.g., oil-in-water and water-in-oil), suppositories, pessaries, gels, pastes, ointments, creams, lotions, oils, as well as patches, bandages, depots, and reservoirs.

[0182] Formulations suitable for transdermal administration include gels, pastes, ointments, creams, lotions, and oils, as well as patches, adhesive plasters, bandages, wound dressings, depots, and reservoirs.

[0183] Tablets can be manufactured by conventional means, such as compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine a free-flowing form of compound such as a powder or granules, optionally mixed with one or more binders (e.g., povidone, gelatin, acacia, sorbitol, tragacanth, hydroxypropylmethylcellulose), fillers or diluents (e.g., lactose, microcrystalline cellulose, calcium hydrogen phosphate), lubricants (e.g., magnesium stearate, talc, silica), disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethylcellulose), surfactants or dispersants or wetting agents (e.g., sodium lauryl sulfate), preservatives (e.g., methyl p-hydroxybenzoate, propyl p-hydroxybenzoate, sorbic acid), flavoring agents, flavor enhancers, and sweeteners. Molded tablets can be manufactured by molding a mixture of powdered compound moistened with an inert liquid diluent in a suitable machine. The tablets may be optionally coated or scored and may be formulated to provide slow or controlled release of the compound in the tablet, for example using various percentages of hydroxypropylmethylcellulose to provide the desired release profile. The tablets may optionally include a coating to affect release, for example an enteric coating to provide release in parts of the intestine other than the stomach.

[0184] An ointment is typically prepared from the compound and a paraffinic or a water-miscible ointment base.

[0185] Creams are typically prepared from the above-mentioned compound and an oil-in-water cream base. If desired, the aqueous phase of the cream base can contain, for example, at least about 30% w / w of polyhydric alcohol, i.e., alcohols with two or more hydroxyl groups, such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol, and mixtures thereof. Topical formulations can desirably contain a compound that enhances the absorption or penetration of the above-mentioned compound through the skin or other affected areas. Examples of such percutaneous penetration enhancers include dimethylsulfoxide and related analogues.

[0186] Emulsions are typically prepared from the above compounds and an oil phase, which may optionally contain only an emulsifier (also known as emulgent) or may contain a mixture of at least one emulsifier with fat or oil or with both fat and oil.Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier that acts as a stabilizer.It is also preferred to include both oil and fat.As a whole, the emulsifier(s) with or without stabilizer(s) constitute the so-called emulsifying wax, which together with oil and / or fat constitutes the so-called emulsifying ointment base that forms the oily dispersed phase of cream formulations.

[0187] Suitable emulgents and emulsion stabilizers include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate and sodium lauryl sulfate. The selection of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of compounds in most oils likely to be used in pharmaceutical emulsion formulations may be very low. For this reason, the cream should preferably be a non-greasy, non-staining, water-removable product with a suitable viscosity to avoid leakage from tubes or other containers. Linear or branched monobasic or dibasic alkyl esters such as diisoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acid, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate, or a blend of branched esters known as crodamol CAP can be used, the last three being the preferred esters. These can be used alone or in combination, depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and / or liquid paraffin or other mineral oils can be used.

[0188] Formulations suitable for intranasal administration include those in which the carrier is a liquid, including, for example, aqueous or oily solutions of the compound, nasal spray, nasal drops, or by aerosol administration by nebulizer.

[0189] Formulations suitable for intranasal administration, where the carrier is a solid, include formulations provided as a coarse powder, for example having a particle size in the range from about 20 to about 500 microns, to be administered in the manner of sniffing, i.e., by rapid inhalation through the nasal passage from a container of the powder held close to the nose.

[0190] Formulations suitable for pulmonary administration (e.g., by inhalation or insufflation therapy) include those delivered as an aerosol spray from pressurized packs by use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.

[0191] Formulations suitable for administration to the eye include eye drops wherein the compound is dissolved or suspended in a suitable carrier, especially an aqueous solvent for the compound.

[0192] Formulations suitable for rectal administration may be provided as a suppository with a suitable base comprising, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols, such as cocoa butter or salicylates, or as solutions or suspensions for enema treatment.

[0193] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing, in addition to the compounds, such carriers as are known in the art to be appropriate.

[0194] Suitable formulations for parenteral administration (e.g., by injection) include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions) in which the compound is dissolved, suspended, or otherwise provided (e.g., in liposomes or other microparticles). Such liquids may additionally contain other pharma- ceutically acceptable components, such as antioxidants, buffers, preservatives, stabilizers, bacteriostats, suspending agents, thickening agents, and solutes that render the formulation isotonic with the blood (or other relevant bodily fluids) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like. Examples of isotonic carriers suitable for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection, and the like. Typically, the concentration of the compound in the liquid is about 1 ng / mL to about 10 μg / mL, for example, about 10 ng / mL to about 1 μg / mL. The formulations can be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier (for example, water for injections) immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets.

[0195] (Dosage) Those skilled in the art will understand that appropriate dosages of BOBA compounds and compositions containing BOBA compounds may vary from patient to patient. Determining optimal dosage will generally involve balancing the level of therapeutic benefit against any risk or adverse side effects. The selected dosage level will be determined by a variety of factors, such as, for example, the activity of the particular BOBA compound, the route of administration, the time of administration, the rate of excretion of the BOBA compound, the duration of treatment, other drugs, compounds, and / or materials used in combination, the severity of the condition, and the type, sex, age, weight, condition, overall health, and medical history of the patient. The amount and route of administration of the BOBA compound will ultimately be at the discretion of the physician, veterinarian, or clinician, but generally, the dosage will be selected to achieve a local concentration at the site of action that achieves the desired effect without causing substantially harmful or deleterious side effects.

[0196] Administration can be in one dose, continuous doses, or intermittent doses (e.g., divided doses at appropriate intervals) throughout the treatment period. Methods of determining the most effective means and dosages of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and administration pattern being selected by the treating physician, veterinarian, or clinician.

[0197] In general, a suitable dosage of a BOBA compound is within the range of about 10 μg to about 20 mg (more typically about 100 μg to about 10 mg, e.g., about 1 mg) per kilogram of subject body weight per day. Where the compound is a salt, ester, amide, prodrug, or the like, the amount administered is calculated based on the parent compound, and thus the actual weight used will be increased proportionately. EXAMPLES

[0198] (chemical synthesis) As noted above, methods for the chemical synthesis of BOBA compounds as described herein can be found, for example, in Borthwick et al., 2016, the contents of which are incorporated herein by reference, see in particular pages 35-48 (General Methods) and 63-94 (Exemplary Methods) therein.

[0199] Additional methods for the chemical synthesis of BOBA-001 as described herein can be found, for example, in Borthwick et al., 2017, the contents of which are incorporated herein by reference. See especially pages 21-28 therein.

[0200] These and / or other known methods can be modified and / or adapted in known manners to facilitate the synthesis of additional BOBA compounds.

[0201] For easy reference, the details of the chemical synthesis of BOBA-001 are set forth below.

[0202] One synthetic route for the preparation of BOBA-001 is described in Borthwick et al., 2016, and is shown in Scheme 1 below.

[0203] Scheme 1 [ka]

[0204] In this method, 2,5-dimethylphenol (1) is reacted with paraformaldehyde to give 2-hydroxy-3,6-dimethylbenzaldehyde (2), which is reacted with tert-butyl 2-bromoacetate to give tert-butyl 4,7-dimethylbenzofuran-2-carboxylate (3) and deprotected to give 4,7-dimethylbenzofuran-2-carboxylic acid (4). This acid is then reacted with methyl 4-(N'-hydroxycarbamimidoyl)benzoate (5) to give methyl 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoate (6), which is then deprotected to give the desired compound, 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (BOBA-001).

[0205] An example of this synthetic route is provided below. Step 1: 2-Hydroxy-3,6-dimethylbenzaldehyde (2) [ka]

[0206] A suspension of 2,5-dimethylphenol (1) (20 g, 160 mmol), paraformaldehyde (34 g, 1.1 mol), MgCl2 (23.4 g, 246 mmol) and Et3N (86 mL, 610 mmol) in anhydrous MeCN (550 mL) was stirred under reflux for 2 h. The reaction mixture was concentrated in vacuo to half volume and partitioned between Et2O (200 mL) and 1 M HCl (200 mL). The aqueous phase was further extracted with Et2O (400 mL) and the combined organic extracts were dried over MgSO4 and filtered. The solution was concentrated in vacuo and the residue was purified by silica gel chromatography (330 g, 0-20% Et2O in hexanes) to give the title compound (2) (8.6 g, 35%) as a yellow solid: 1H NMR(400MHz, DMSO-d6)δ: 12.12(1H, s), 10.29(1H, s), 7.25(1H, d), 6.61(1H, d), 2.56(3H, s), 2.20(3H, s).

[0207] Step 2: tert-Butyl 4,7-dimethylbenzofuran-2-carboxylate (3) [ka]

[0208] 2-tert-Butyl bromoacetate (10.6 mL, 71.5 mmol) was added dropwise to a stirred suspension of 2-hydroxy-3,6-dimethylbenzaldehyde (2) (8.6 g, 57 mmol) and potassium carbonate (19.8 g, 143 mmol) in anhydrous DMF (40 mL). The reaction mixture was stirred under reflux for 20 h. The mixture was partitioned between EtOAc (100 mL) and water (100 mL) and the aqueous phase was further extracted with EtOAc (100 mL). The combined organics were washed with brine (5x100 mL) and concentrated in vacuo. The residue was purified by silica gel chromatography (330 g, 20% MeOH in dichloromethane (DCM)) to give the title compound (3) (12.3 g, 87% yield) as a red oil: 1 H NMR (400 MHz, DMSO-d6)δ: 7.42(1H, s), 7.04(2H, dd), 8.33(1H, d), 2.52(3H, s), 2.50(3H, s), 1.63(9H, s).

[0209] Step 3: 4,7-Dimethylbenzofuran-2-carboxylic acid (4) [ka]

[0210] Trifluoroacetic acid (TFA) (19.2 mL, 249 mmol) was added dropwise to a solution of tert-butyl 4,7-dimethylbenzofuran-2-carboxylate (3) (12.3 g, 49.8 mmol) in DCM (100 mL) at 0 °C. After the addition, the mixture was warmed to room temperature and stirred for 20 h. The solvent was removed in vacuo and the residue was partitioned between EtOAc (100 mL) and 1 M HCl (100 mL). The aqueous phase was further extracted with EtOAc (100 mL) and the combined organic phases were washed with brine (300 mL) and then concentrated in vacuo. The residue was dissolved in EtOAc (100 mL) and then extracted with saturated NaHCO3 solution (200 mL). The aqueous solution was acidified by the addition of concentrated HCl and extracted with EtOAc (200 mL). The organic solution was concentrated in vacuo and co-evaporated with toluene to give the title compound (4) (7.7 g, 81% yield) as a light brown solid: m / z 190 [M+H] + (ES + ). 1 H NMR (400 MHz, DMSO-d6)δ: 13.48(1H, s), 7.72(1H, s), 7.11(2H, dd), 2.47(3H, s), 2.44(3H, s).

[0211] Step 4: Methyl 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoate (6) [ka]

[0212] A solution of 2-propanephosphonic anhydride (T3P) (23.2 mL, 39.4 mmol) in EtOAc (50%) was added dropwise to a mixture of 4,7-dimethylbenzofuran-2-carboxylic acid (4) (3.0 g, 16 mmol), methyl 4-(N'-hydroxycarbamimidoyl)benzoate (5) (3.1 g, 16 mmol) and Et3N (11 mL, 79 mmol) in anhydrous N,N-dimethylformamide (25 mL) at 0°C. The mixture was stirred at 0°C for 10 min, then warmed to 90°C and stirred for 18 h. The reaction mixture was cooled to room temperature and poured into ice water (150 mL). The solid was collected, washed with cold EtOAc and dried under suction. Purification by trituration with MeOH and drying in vacuum afforded the title compound (6) (3.6 g, 65% yield) as a light pink solid: m / z 349 [M+H] + (ES + ). 1 H NMR(400 MHz, DMSO-d6)δ: 8.29-8.26(3H, m), 8.19(2H, d), 7.29(1H, d), 7.13(1H, d), 3.92(3H, s), 2.56(3H, s), 2.54(3H, s).

[0213] Step 5: 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (BOBA-001) [ka]

[0214] A suspension of methyl 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoate (6) (100 mg, 0.287 mmol) in tetrahydrofuran (THF) (1 mL) was treated with LiOH (2 M, aq., 720 μL, 1.4 mmol) and the mixture was stirred at 40° C. for 20 h. The reaction mixture was cooled to room temperature and then acidified by the dropwise addition of 1 M HCl. The resulting solid was collected by filtration, then dissolved in MeOH and evaporated to dryness to give the title compound (BOBA-001) (95 mg, 99% yield) as a white solid: m / z 335 [M+H] + (ES + ), 333 [MH] - (ES). 1 H NMR(400 MHz, DMSO-d6)δ: 13.34(1H, br. s), 8.25-8.23(3H, m), 8.16(2H, d), 7.29(1H, d), 7.12(1H, d), 2.56(3H, s), 2.53(3H, s).

[0215] Another method for preparing BOBA-001 is shown below in Scheme 2. Scheme 2 [ka] TIFF0007595033000017.tif88152

[0216] In this method, methyl 4-cyanobenzoate (III) is treated with aqueous hydroxylamine in methanol. After the reaction is complete, methyl tert-butyl ether (MTBE) is added, the mixture is cooled, and the product, methyl 4-(N'-hydroxycarbamimidoyl)benzoate (IV), is isolated as a solid after overnight aging.

[0217] 4,7-Dimethylbenzofuran-2-carboxylic acid (I) is treated with oxalyl chloride in dichloromethane in the presence of catalytic N,N-dimethylformamide. After the reaction is complete, the solution containing the product, 4,7-dimethylbenzofuran-2-carbonyl chloride (II), is telescoped and carried forward to the next step.

[0218] 4,7-Dimethylbenzofuran-2-carbonyl chloride (II) is treated with methyl 4-(N'-hydroxycarbamimidoyl)benzoate (IV) in the presence of triethylamine as base and 2-butanone as solvent. After removal of the solvent, the penultimate intermediate methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoate (VI) is crystallized from methanol and isolated by filtration.

[0219] Methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoate (VI) is hydrolyzed by treatment with potassium hydroxide in tetrahydrofuran (THF) at 60-65°C, then diluted with water and ethanol. Upon addition of concentrated hydrochloric acid, the target compound, 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid (BOBA-001), precipitates and is isolated by filtration.

[0220] An example of this synthetic route is provided below. Step 1: Methyl 4-(N'-hydroxycarbamimidoyl)benzoate (IV) [ka]

[0221] A solution of methyl 4-cyanobenzoate (III) (2.50 kg, 1 wt) in methanol (7.5 L, 3 vol) was diluted with methyl tert.-butyl ether (9.3 kg, 3.7 wt). Aqueous hydroxylamine (50% solution; 1.23 kg, 0.5 wt, 1.2 eq.) was dosed over approximately 0.5 h at 20-25 °C. The dosing line was rinsed with methanol (1 kg, 0.4 wt) and the reaction was allowed to proceed for approximately 12 h at 20-25 °C. The batch was cooled to 5 ± 5 °C and aged for 3 h at 5 ± 5 °C. The product, methyl 4-(N'-hydroxycarbamimidoyl)benzoate (IV), was isolated by filtration, washed with methyl tert.-butyl ether (2x5.5 kg, 2x2.2 wt) and dried at ambient temperature under a stream of nitrogen for about 4 hours (2.38 kg, 93%).

[0222] Step 2: 4,7-Dimethylbenzfuran-2-carbonyl chloride (II) [ka]

[0223] A reactor was charged with 4,7-dimethylbenzofuran-2-carboxylic acid (I) (1.96 kg, 1 wt), N,N-dimethylformamide (8 g, 0.004 wt) and dichloromethane (6.85 kg, 3.5 wt) and the batch was heated to 25-30°C. Over approximately 15 minutes, oxalyl chloride (1.47 kg, 0.75 wt, 1.1 eq) was dosed into the mixture and the dose line was rinsed with dichloromethane (1.3 kg, 0.66 wt). The batch was stirred at 30-35°C for approximately 1.5 hours and the resulting product, 4,7-dimethylbenzofuran-2-carbonyl chloride (II), was used directly in the next step without further purification.

[0224] Step 3: Methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoate (VI) [ka]

[0225] The reactor was charged with methyl 4-(N'-hydroxycarbamimidoyl)benzoate (IV) (1.97 kg, 1 wt, 0.97 eq based on (I)), triethylamine (2.34 kg, 1.2 wt, 2.2 eq) and methyl isobutyl ketone (23.9 kg, 12 wt). The batch was heated to 30-35°C and dosed with the solution of 4,7-dimethylbenzofuran-2-carbonyl chloride (II) (prepared in step 2) while ensuring that the temperature did not exceed 60°C. The dosing line was rinsed with dichloromethane (0.66 wt) and heated at atmospheric pressure at 110-115°C for approximately 3 hours after first distilling off some of the solvent. The batch was cooled to 60-70°C, methanol (8 kg, 4 wt) was added and the batch was heated at this temperature for an additional 30 minutes. The batch was cooled to 20±3° C. and aged at this temperature for approximately 1 hour. The solid product was filtered, washed with methanol (2×6.2 kg, 2×3.1 wt) and dried under a nitrogen stream at ambient temperature for 16 hours (3.3 kg, 93%).

[0226] Step 4: 4-[5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoic acid (BOBA-001) [ka]

[0227] The reactor was charged with methyl 4-[5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl]benzoate (VI) (3.0 kg, 1 wt), tetrahydrofuran (THF) (22 kg, 7.1 wt) and an aqueous solution of potassium hydroxide prepared from solid KOH (0.69 kg, 0.23 wt) in demineralized water (DEMI water, 7.5 kg, 2.5 wt). The batch was heated to 65±5°C and stirred at 65±5°C for about 3 hours. The batch was cooled to 30-35°C and the reaction mixture was discharged. The solution was charged to the reactor through an in-line filter (i.e., clarification step). The reactor was charged with DEMI water (6 kg, 2.0 wt) and absolute ethanol (9.6 kg, 3.2 wt) through an in-line filter. The batch was heated to 55±5°C. Concentrated hydrochloric acid (30 wt%) (1.35 kg, 0.45 wt) was dosed to the reactor through an in-line filter and the batch was stirred at 55±5° C. for approximately 15 minutes. The batch was cooled to 20±3° C. and aged at this temperature for 2 hours. The product was filtered and the filter cake was washed twice with a mixture of DEMI water (1.5 kg, 0.5 wt) and absolute ethanol (8.4 kg, 2.8 wt). The batch was dried on the filter at ambient temperature for approximately 1 hour to yield the target compound, BOBA-001.

[0228] biological research animal research animal Adult male Sprague-Dawley rats (150-200 g) were housed under a natural light:dark cycle with water and food provided ad libitum. The animals were acclimated to the testing paradigm for 3-5 days prior to data collection. All protocols were approved by the Animal Care and Use Committees of King's College London and the UK Home Office.

[0229] surgery Animals were studied using a standard model for neuropathic pain (lumbar fifth spinal nerve ligation (L5 SNL); see, e.g., Kim et al., 1992), which is the most widely used model in neuropathic pain research due to the high reproducibility of spontaneous and evoked pain (hyperalgesia, allodynia) and the absence of autotomy (see, e.g., Barrot, 2012; Huang et al., 2016).

[0230] Adult rats underwent partial nerve ligation of the left sciatic nerve under isoflurane (Abbott Animal Health) inhalation anesthesia (see, e.g., Seltzer et al., 1990). A small incision was made just above the left thigh to expose the sciatic nerve. The nerve was carefully freed of surrounding connective tissue at a site proximal to the trochanter, just distal to the point where the posterior biceps semitendinosus nerve branches off from the common sciatic nerve. A 5-0 Vicryl suture (Ethicon, UK) was inserted into the nerve and tightly ligated so that 1 / 3–1 / 2 of the nerve thickness was held within the ligature.

[0231] treatment Two groups of 11 rats were studied. In each group, rats underwent partial nerve ligation of the left sciatic nerve (L5 SNL) as described above. In one group, rats were treated with test compound; in the other group, rats were treated with placebo. Eight animals in each group were used for behavioral studies (28 days after surgery) as described below. Three animals in each group were used for histological analysis (14 days after surgery) as described below.

[0232] Rats were treated orally with treatment solution or placebo beginning the day after surgery and every other day thereafter for 4 weeks.

[0233] Treatment solutions were prepared by dissolving 4 mg of test compound (BOBA-001) in 1 mL of 0.1 N aqueous NaHCO3 (to obtain a concentration of approximately 4 mg / mL).

[0234] For treated animals, the treatment solution was administered orally (po) by oral gavage to give a dose of 3 mg / kg.

[0235] Control animals were given a corresponding volume of vehicle (0.1N NaHCO3 aqueous solution) orally as a placebo by oral gavage (po).

[0236] behavioral research Pain thresholds were measured according to the following method, with baseline measurements taken one day before surgery, and on days 1, 6, 9, 16, 23, and 28 after surgery.

[0237] (Pain Threshold - Mechanical Allodynia) Static mechanical withdrawal thresholds were assessed by applying von Frey hairs (Touch Test, Stoelting, IL, USA) to the plantar surface of the hind paws. Unrestrained animals were habituated for 60 minutes prior to testing on a wire mesh grid in an acrylic cubicle (8x5x10 cm). Calibrated von Frey hairs (multiple flexible nylon fibers of increasing diameter that exert a defined level of force) were applied to the plantar surface of the hind paw until the fibers bent. The hairs were held in place for 3 seconds or until the paw withdrew in a reflex that was not accompanied by movement or grooming. Each hair was applied five times, alternating between the left paw (ipsilateral to the peripheral nerve injury) and the right paw (contralateral to the peripheral nerve injury), starting with the hair with the lowest force. Hairs were applied sequentially with increasing force (five applications per hair). A positive response was recorded if a 40% withdrawal response occurred over five applications.

[0238] Figure 1 is a graph of mechanical paw withdrawal threshold (grams) versus time after surgery (days) for (a) treatment with placebo, ipsilateral to peripheral nerve injury (open circles); (b) treatment with placebo, contralateral to peripheral nerve injury (open diamonds); (c) treatment with BOBA-001, ipsilateral to peripheral nerve injury (closed circles); (d) treatment with BOBA-001, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001.

[0239] (Pain threshold - Thermal hyperalgesia - Hot plate) Thermal hyperalgesia was assessed using a modified method from Hargreaves et al., 1988. Briefly, rats were habituated for 10 min to the apparatus, which consisted of individual plexiglass boxes on a lifting glass table. A mobile radiant heat source was placed under the table and focused on the hind paw, and paw withdrawal latency was defined as the time it took the rat to remove its hind paw from the heat source. The cut-off point was set at 25 s to prevent tissue damage. The apparatus was calibrated to give a paw withdrawal latency of approximately 15 s in naive rats. Three recordings, separated by at least 5 min, were averaged for both the left paw (ipsilateral to the peripheral nerve injury) and the right paw (contralateral to the peripheral nerve injury).

[0240] Figure 2 is a graph of hot plate paw withdrawal (seconds) versus time after surgery (days) for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo treatment, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001.

[0241] (Pain Threshold - Thermal Hyperalgesia - Cold Plate) Hind paw withdrawal in response to a painful cold stimulus was assessed using an incremental hot / cold plate (IITC Life Sciences) set at 4±0.1°C. Rats were lightly restrained and the hind paw was held with the plantar surface against the cold plate. Paw withdrawal latency was measured to the nearest 0.01 s. To avoid tissue damage, the maximum latency period allowed was 20 s. Three recordings, at least 5 min apart, were averaged for both the left paw (ipsilateral to the peripheral nerve injury) and the right paw (contralateral to the peripheral nerve injury). Rats were not tested on the 9th day after surgery.

[0242] Figure 3 is a graph of cold plate paw withdrawal (seconds) versus time after surgery (days) for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001.

[0243] (Pain Threshold - Randall Sellito Test) Mechanical nociceptive thresholds were assessed using an Analgesy-Meter (Ugo Basile, Comerio, Italy) (see, e.g., Raghavendra et al., 2003). Rats were gently held and gradually increasing pressure (up to 25 g) was applied to the dorsal surface of the hind paw. This pressure was required to induce paw withdrawal and the paw pressure threshold (grams) was determined. Three recordings, at least 5 min apart, were averaged for both the left paw (ipsilateral to the peripheral nerve injury) and the right paw (contralateral to the peripheral nerve injury). Rats were not tested on the 9th day after surgery.

[0244] Figure 4 is a graph of Randall Sellito paw withdrawal threshold (grams) versus time after surgery (days) for (a) placebo treatment, ipsilateral to peripheral nerve injury (open circles); (b) placebo, contralateral to peripheral nerve injury (open diamonds); (c) BOBA-001 treatment, ipsilateral to peripheral nerve injury (closed circles); (d) BOBA-001 treatment, contralateral to peripheral nerve injury (closed diamonds). Data are reported as mean ± standard error of the mean (SEM); 8 animals per group (n=8); 2-way repeated measures ANOVA: **p≦0.01; ***p≦0.001.

[0245] (result) The above data show that rats that underwent L5 SNL and were treated with BOBA-001 for four weeks showed significant improvements in thermal and mechanical threshold testing and enjoyed significant relief of pain compared to rats treated with placebo.

[0246] The above data show that treatment with BOBA-001 reduces mechanical and thermal hypersensitivity and restores mechanical and thermal sensitivity following nerve injury, which is surprising and unexpected in light of the fact that BOBA-001 also induces axonal outgrowth.

[0247] tissue analysis We measured the levels of markers associated with neuropathic pain in the dorsal horn and dorsal root ganglion ipsilateral and contralateral to the peripheral nerve injury: (1) tumor necrosis factor-α (TNF-α), involved in the initiation of NP (see, e.g., Schafers et al., 2003A); (2) TNFR1, upregulated after SNL (see, e.g., Schafers et al., 2003B); and (3) brain-derived neurotrophic factor (BDNF), which, apart from its effects on pre- and postsynaptic inhibition (see, e.g., Meacham et al., 2017), has been shown to be involved in synaptic plasticity and central sensitization in Schaffer collaterals (SC) and to contribute to the development and maintenance of neuropathic pain by activation of dorsal horn NR2B-containing NMDA (NMDA-2B) receptors (see, e.g., Geng et al., 2010).

[0248] Total RNA isolation and RT-qPCR analysis Fourteen days after injury, three rats from each group were sacrificed. Spinal cords were isolated from the injury area and lysed using a Teflon glass homogenizer and QIAshredder columns (Qiagen). Total RNA was isolated with a Qiagen RNeasy® Mini Kit and reverse transcribed with a QuantiTect® Reverse Transcription Kit (Qiagen). For each gene, the levels of tumor necrosis factor alpha (TNFα) and tumor necrosis factor receptor 1 (TNFR1) expression were quantified in triplicate against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and triple non-template controls by RT-qPCR analysis on a LightCycler® 480 instrument using LightCycler® SYBR® Green I Master Reagent (Roche).

[0249] The primer pairs used were: TNFα forward: 5′-CTGTGCCTCAGCCTCTTCTC-3′; TNFα reverse: 5′-ACTGATGAGAGGGAGCCCAT-3′; TNFR1 forward: 5'-CCTCTCTCCCCTCGGCTTTA-3'; TNFR1 reverse: 5'-CCCGGGTTAGAAAGGCTCAA-3'; GAPDH forward: 5'-TGACCTCAACTACATGGTCTACA-3'; and GAPDH reverse: 5'-GACTCCACGACATACTCAGCA-3'.

[0250] RT-qPCR cycling parameters were optimized for each gene and were as follows: an initiation step of 95°C for 5 min, followed by 45 cycles of 95°C, 10 s; 60°C, 20 s; 72°C, 10 s.

[0251] Figure 5 is a bar graph showing the TNFα:GAPDH expression ratio in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Three animals per group (n=3). Data are reported as mean ± standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001.

[0252] Figure 6 is a bar graph showing TNFR1:GAPDH expression ratios in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Three animals per group (n=3). Data are reported as mean ± standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001.

[0253] (Immunocytochemistry (IHC)) Spinal cord tissue embedded in paraffin wax was first dewaxed in xylene and 100% industrial methylated alcohol (IMS), then heated in citric acid (10 mM, pH 6) until boiling, and then washed under running tap water for 5 min. The sections were washed 3x 5 min each in phosphate buffered saline (PBS), and then incubated with primary antibodies in PBS-0.02% Tween at 4°C overnight. Primary antibodies were removed by washing 3x 5 min each in PBS. Samples were then incubated in secondary antibodies in PBS-0.02% Tween at room temperature for 1 h, followed by washing 3x 5 min each in PBS. The antibodies used were as follows: BDNF antibody (Novuf Biologicals, NBP1-46750) and AlexaFluor™ 594.

[0254] Multichannel fluorescence (DAPI-FITC-Texas Red filter set) images were captured using a Zeiss LSM 700 laser scanning confocal microscope. For high magnification images, a 63x oil immersion apochromatic objective (Carl Zeiss) was used. All sections were digitized under the same illumination conditions, with settings for gain, aperture, contrast and brightness initially optimized and kept constant throughout each study. Multiple channels were imaged sequentially to remove bleed through, and multichannel image overlays were obtained using Adobe Photoshop 7.0 (Adobe Systems). Axiovision software was used to collect information on pixel immunoreactivity used for quantification purposes. All statistical analyses were performed using SigmaSTAT software (SPSS Software Ltd, Birmingham, UK).

[0255] Figure 7 is a bar graph showing BDNF levels (arbitrary units) in the dorsal horn ipsilateral to peripheral nerve injury for (a) placebo-treated rats and (b) BOBA-001-treated rats. Five serial sections per injured spinal cord analyzed, three animals per group (n=3). Data are reported as mean ± standard error of the mean (SEM); Student's t-test: **p≦0.01, ***p≦0.001.

[0256] result The above data show that after nerve injury, treatment with BOBA-001 regulates TNFα, TNFR1, and BDNF. The expression levels of these three markers (TNFα, TNFR1, and BDNF) in the dorsal horn ipsilateral to injury were significantly downregulated after treatment with BOBA-001 compared to placebo. These results strongly suggest a regulatory effect on the pathway leading to neuropathic pain.

[0257] The above has described the principles, preferred embodiments, and modes of operation of the present invention. However, the present invention should not be construed as being limited to the particular embodiments discussed. Instead, the above-described embodiments should be considered as illustrative rather than restrictive. It should be recognized that modifications may be made by those skilled in the art in these embodiments without departing from the scope of the present invention. The present invention includes, for example, the following aspects. [Section 1] 2. A compound of the following formula, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof, for use in a method for the treatment or prophylaxis of neuropathic pain: [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C is -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and; -R Q5Ais a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHR P2DD , or -NR P2DD2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) Alternatively, a pharmaceutical composition comprising such a compound and a pharma- ceutically acceptable carrier, diluent, or excipient. [Section 2] 2. The method of claim 1, wherein the compound of the formula: [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A, -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C is -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and; -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHR P2DD , or -NR P2DD 2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) Use of. [Section 3] A method for treating or preventing neuropathic pain, comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of the following formula, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4Cis -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and; -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2Bis independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHR P2DD , or -NR P2DD 2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) Alternatively, a pharmaceutical composition comprising such a compound and a pharma- ceutically acceptable carrier, diluent, or excipient. The method comprises administering [Section 4] 1. A method for the treatment or prevention of neuropathic pain comprising the steps of: [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C is -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and; -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -RP1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHR P2DD , or -NR P2DD 2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) Alternatively, a pharmaceutical composition comprising such a compound and a pharma- ceutically acceptable carrier, diluent, or excipient. Use of. [Section 5] A compound of the following formula: or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: [ka] (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and; -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C is -CF3; -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and; -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C is -CF3; -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and; -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C is -CF3; -R Q4are independently -H, -R Q4A , -R Q4B , or -R Q4C and; -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C is -CF3; -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and; -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C is -CF3; -R P1 are independently -H or -R P1X and; -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and; -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C is -CF3; -R P1D are independently -NH2, -NHR P1DD , or -NR P1DD 2 and; -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -RP2X and; -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and; -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C is -CF3; -R P2D are independently -NH2, -NHR P2DD , or -NR P2DD 2 and; -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and; -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) Alternatively, a pharmaceutical composition comprising such a compound and a pharma- ceutically acceptable carrier, diluent, or excipient; and instructions for use for the treatment or prevention of neuropathic pain. Kit including: [Section 6] -R Q1 -R Q1A That is, A compound or pharmaceutical composition for use according to item 1. Use of the compound according to item 2, The method according to item 3, Use of the compound or pharmaceutical composition according to item 4, or Item 6. The kit according to item 5. [Section 7] -R Q1 -R Q1B That is, A compound or pharmaceutical composition for use according to item 1. Use of the compound according to item 2, The method according to item 3, Use of the compound or pharmaceutical composition according to item 4, or Item 6. The kit according to item 5. [Section 8] -R Q1 -R Q1C That is, A compound or pharmaceutical composition for use according to item 1. Use of the compound according to item 2, The method according to item 3, Use of the compound or pharmaceutical composition according to item 4, or Item 6. The kit according to item 5. [Section 9] -R Q2 -R Q2A That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 8. Use of the compound according to any one of items 2 and 6 to 8, The method according to any one of items 3 and 6 to 8, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 8. Item 9. The kit according to any one of Items 5 to 8. [Section 10] -R Q2 -R Q2B That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 8. Use of the compound according to any one of items 2 and 6 to 8, The method according to any one of items 3 and 6 to 8, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 8. Item 9. The kit according to any one of Items 5 to 8. [Section 11] -R Q2 -R Q2C That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 8. Use of the compound according to any one of items 2 and 6 to 8, The method according to any one of items 3 and 6 to 8, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 8. Item 9. The kit according to any one of Items 5 to 8. [Section 12] -R Q3 is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 11. Use of the compound according to any one of items 2 and 6 to 11, The method according to any one of items 3 and 6 to 11, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 11; Item 12. The kit according to any one of Items 5 to 11. [Section 13] -R Q4 is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 12, Use of the compound according to any one of items 2 and 6 to 12, The method according to any one of items 3 and 6 to 12, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 12, Item 13. The kit according to any one of Items 5 to 12. [Section 14] -R Q5 is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 13, Use of the compound according to any one of items 2 and 6 to 13, The method according to any one of items 3 and 6 to 13, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 13, Item 14. The kit according to any one of Items 5 to 13. [Section 15] -R Q5 -R Q5A That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 13, Use of the compound according to any one of items 2 and 6 to 13, The method according to any one of items 3 and 6 to 13, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 13, Item 14. The kit according to any one of Items 5 to 13. [Section 16] -R Q1A is present, then -Me; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 15. Use of the compound according to any one of items 2 and 6 to 15, The method according to any one of items 3 and 6 to 15, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 15; Item 16. The kit according to any one of Items 5 to 15. [Section 17] -R Q2A is present, then -Me; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 16, Use of the compound according to any one of items 2 and 6 to 16, The method according to any one of items 3 and 6 to 16, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 16, Item 17. The kit according to any one of Items 5 to 16. [Section 18] -R Q5A is present, then -Me; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 17, Use of the compound according to any one of items 2 and 6 to 17, The method according to any one of items 3 and 6 to 17, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 17; Item 18. The kit according to any one of Items 5 to 17. [Section 19] -R Q1B is -F, if present, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 18, Use of the compound according to any one of items 2 and 6 to 18, The method according to any one of items 3 and 6 to 18, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 18; Item 19. The kit according to any one of items 5 to 18. [Section 20] -R Q1B is -Cl, if present; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 18, Use of the compound according to any one of items 2 and 6 to 18, The method according to any one of items 3 and 6 to 18, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 18; Item 19. The kit according to any one of items 5 to 18. [Section 21] -R Q2B is -F, if present, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 20. Use of the compound according to any one of items 2 and 6 to 20, The method according to any one of items 3 and 6 to 20, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 20; 21. The kit according to any one of items 5 to 20. [Section 22] -R Q2B is -Cl, if present; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 20. Use of the compound according to any one of items 2 and 6 to 20, The method according to any one of items 3 and 6 to 20, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 20; 21. The kit according to any one of items 5 to 20. [Section 23] -R P1 is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 22. Use of the compound according to any one of items 2 and 6 to 22, The method according to any one of items 3 and 6 to 22, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 22; Item 23. The kit according to any one of Items 5 to 22. [Section 24] -R P1 -R P1X That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 22. Use of the compound according to any one of items 2 and 6 to 22, The method according to any one of items 3 and 6 to 22, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 22; Item 23. The kit according to any one of Items 5 to 22. [Section 25] -R P2 is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 24. Use of the compound according to any one of items 2 and 6 to 24, The method according to any one of items 3 and 6 to 24, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 24; Item 25. The kit according to any one of items 5 to 24. [Section 26] -R P2 -R P2X That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 24. Use of the compound according to any one of items 2 and 6 to 24, The method according to any one of items 3 and 6 to 24, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 24; Item 25. The kit according to any one of items 5 to 24. [Section 27] -R P1X If present, -R P1A That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 26. Use of the compound according to any one of items 2 and 6 to 26, The method according to any one of items 3 and 6 to 26, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 26; Item 27. The kit according to any one of items 5 to 26. [Section 28] -R P1X If present, -R P1B That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 26. Use of the compound according to any one of items 2 and 6 to 26, The method according to any one of items 3 and 6 to 26, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 26; Item 27. The kit according to any one of items 5 to 26. [Section 29] -R P1X If present, -R P1C That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 26. Use of the compound according to any one of items 2 and 6 to 26, The method according to any one of items 3 and 6 to 26, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 26; Item 27. The kit according to any one of items 5 to 26. [Section 30] -R P2X If present, -R P2A That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 29. Use of the compound according to any one of items 2 and 6 to 29, The method according to any one of items 3 and 6 to 29, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 29; Item 30. The kit according to any one of items 5 to 29. [Section 31] -R P2X If present, -R P2B That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 29. Use of the compound according to any one of items 2 and 6 to 29, The method according to any one of items 3 and 6 to 29, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 29; Item 30. The kit according to any one of items 5 to 29. [Section 32] -R P2X If present, -R P2C That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 29. Use of the compound according to any one of items 2 and 6 to 29, The method according to any one of items 3 and 6 to 29, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 29; Item 30. The kit according to any one of items 5 to 29. [Section 33] -R P1A is present, then -Me; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 32, Use of the compound according to any one of items 2 and 6 to 32, The method according to any one of items 3 and 6 to 32, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 32, Item 33. The kit according to any one of Items 5 to 32. [Section 34] -R P2A is present, then -Me; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 33. Use of the compound according to any one of items 2 and 6 to 33, The method according to any one of items 3 and 6 to 33, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 33; Item 34. The kit according to any one of Items 5 to 33. [Section 35] -R P1B is -F, if present, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 34, Use of the compound according to any one of items 2 and 6 to 34, The method according to any one of items 3 and 6 to 34, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 34; Item 35. The kit according to any one of Items 5 to 34. [Section 36] -R P1B is -Cl, if present; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 34, Use of the compound according to any one of items 2 and 6 to 34, The method according to any one of items 3 and 6 to 34, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 34; Item 35. The kit according to any one of Items 5 to 34. [Section 37] -R P2B is -F, if present, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 36, Use of the compound according to any one of items 2 and 6 to 36, The method according to any one of items 3 and 6 to 36, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 36, Item 37. The kit according to any one of Items 5 to 36. [Section 38] -R P2B is -Cl, if present; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 36, Use of the compound according to any one of items 2 and 6 to 36, The method according to any one of items 3 and 6 to 36, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 36, Item 37. The kit according to any one of Items 5 to 36. [Section 39] -R A is -H, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 38. Use of the compound according to any one of items 2 and 6 to 38, The method according to any one of items 3 and 6 to 38, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 38; Item 39. The kit according to any one of items 5 to 38. [Section 40] The compound is a compound of one of the following formulas, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: [ka] JPEG0007595033000028.jpg213140JPEG0007595033000029.jpg212143, A compound or pharmaceutical composition for use according to item 1. Use of the compound according to item 2, The method according to item 3, Use of the compound or pharmaceutical composition according to item 4, or Item 6. The kit according to item 5. [Section 41] The compound is of the following formula: or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: [ka] That is, A compound or pharmaceutical composition for use according to item 1. Use of the compound according to item 2, The method according to item 3, Use of the compound or pharmaceutical composition according to item 4, or Item 6. The kit according to item 5. [Section 42] Neuropathic pain is: Peripheral neuropathic pain; Central neuropathic pain; Chronic neuropathic pain; Intractable neuropathic pain; Neuropathic pain associated with metabolic dysfunction, such as diabetes and prediabetes; Neuropathic pain associated with diabetes; Neuropathic pain associated with prediabetes; Neuropathic pain associated with painful polyneuropathy; Neuropathic pain associated with painful diabetic neuropathy, such as diabetic peripheral neuropathy; Neuropathic pain associated with painful diabetic polyneuropathy; Neuropathic pain associated with postherpetic neuralgia; Neuropathic pain associated with trigeminal neuralgia; Neuropathic pain associated with occipital neuralgia; Neuropathic pain associated with painful radiculopathies, such as lumbar and cervical radiculopathies; Neuropathic pain associated with infectious diseases, such as herpes zoster (shingles), HIV infection, Lyme disease, diphtheria and leprosy; Neuropathic pain associated with liver or kidney disorders, such as chronic liver or kidney disorders, such as liver disease, liver failure, kidney disease, and kidney failure; Neuropathic pain associated with immune or inflammatory disorders, such as Guillain-Barre syndrome, rheumatoid arthritis, lupus, Sjogren's syndrome, and celiac disease; Neuropathic pain associated with inherited neuropathies or channelopathies, such as hereditary erythromelalgia, paroxysmal acute pain syndrome, and Charcot-Marie-Tooth disease (CMT); Neuropathic pain associated with small fiber sensory neuropathy; Neuropathic pain associated with thyroid hormone disorders, e.g. hypothyroidism; Neuropathic pain following stroke; Neuropathic pain associated with cancer, such as lymphoma and multiple myeloma; Chemotherapy, e.g., neuropathic pain associated with cancer chemotherapy; Neuropathic pain associated with peripheral nerve injury pain; Neuropathic pain associated with post-traumatic nerve damage; Neuropathic pain associated with post-traumatic neuropathy; Neuropathic pain following spinal cord injury, such as spinal cord injury caused by trauma, e.g., a traffic accident; Neuropathic pain following traumatic peripheral nerve injury; Neuropathic pain associated with post-surgical neuropathy (e.g., post-operative neuropathic pain); Post-operative neuropathic pain, such as neuropathic pain following neurosurgery, e.g. spinal surgery; Neuropathic pain associated with fibromyalgia; Neuropathic pain associated with low back pain; Neuropathic pain associated with carpal tunnel syndrome; Neuropathic pain accompanied by burning pain; Neuropathic pain associated with reflex sympathetic dystrophy (RSD); Neuropathic pain associated with complex regional pain syndrome (CRPS), such as types 1 and 2; Neuropathic pain following amputation; Neurodegenerative diseases, such as neuropathic pain associated with Parkinson's disease; Neuropathic pain associated with stroke, such as central post-stroke pain; Neuropathic pain associated with syringomyelia; Neuropathic pain associated with demyelinating diseases, such as multiple sclerosis, transverse myelitis, and neuromyelitis optica; or Idiopathic neuropathic pain That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 41. Use of the compound according to any one of items 2 and 6 to 41, The method according to any one of items 3 and 6 to 41, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 41; Item 42. The kit according to any one of Items 5 to 41. [Section 43] Neuropathic pain is: Neuropathic pain associated with metabolic dysfunction, such as diabetes and prediabetes; Neuropathic pain associated with diabetes; Neuropathic pain associated with prediabetes; Neuropathic pain associated with painful diabetic neuropathy, such as diabetic peripheral neuropathy; or Neuropathic pain associated with painful diabetic polyneuropathy That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 41. Use of the compound according to any one of items 2 and 6 to 41, The method according to any one of items 3 and 6 to 41, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 41; Item 42. The kit according to any one of Items 5 to 41. [Section 44] The neuropathic pain is neuropathic pain associated with post-herpetic neuralgia; A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 41. Use of the compound according to any one of items 2 and 6 to 41, The method according to any one of items 3 and 6 to 41, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 41; Item 42. The kit according to any one of Items 5 to 41. [Section 45] Neuropathic pain is: Neuropathic pain associated with peripheral nerve injury pain; Neuropathic pain associated with post-traumatic nerve damage; Neuropathic pain associated with post-traumatic neuropathy; Neuropathic pain following spinal cord injury, such as spinal cord injury caused by trauma, e.g., a traffic accident; Neuropathic pain following traumatic peripheral nerve injury; Neuropathic pain associated with post-surgical neuropathy (e.g., post-surgical neuropathic pain); or Post-operative neuropathic pain, such as neurosurgery, e.g. spinal surgery, etc. That is, A compound or pharmaceutical composition for use according to any one of items 1 and 6 to 41. Use of the compound according to any one of items 2 and 6 to 41, The method according to any one of items 3 and 6 to 41, Use of the compound or pharmaceutical composition according to any one of items 4 and 6 to 41; Item 42. The kit according to any one of Items 5 to 41.

[0258] (References) Numerous publications are cited herein in order to more fully describe and disclose the invention and the state of the art to which this invention pertains. Full citations for these publications are provided below.

[0259] Each of these publications is herein incorporated by reference in its entirety into this disclosure to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. TIFF0007595033000031.tif184160TIFF0007595033000032.tif66156

Claims

1. 1. A pharmaceutical composition for use in a method for the treatment or prevention of neuropathic pain, comprising a compound of the following formula: 【Chemistry 1】 (In the formula: -R Q1 is independently -R Q1A , -R Q1B , or -R Q1C and -R Q1A is a saturated linear or branched chain C 1-4 is alkyl; -R Q1B is independently -F, -Cl, -Br, or -I; -R Q1C -CF 3 and -R Q2 is independently -R Q2A , -R Q2B , or -R Q2C and -R Q2A is a saturated linear or branched chain C 1-4 is alkyl; -R Q2B is independently -F, -Cl, -Br, or -I; -R Q2C -CF 3 and -R Q3 are independently -H, -R Q3A , -R Q3B , or -R Q3C and -R Q3A is a saturated linear or branched chain C 1-4 is alkyl; -R Q3B is independently -F, -Cl, -Br, or -I; -R Q3C -CF 3 and -R Q4 are independently -H, -R Q4A , -R Q4B , or -R Q4C and -R Q4A is a saturated linear or branched chain C 1-4 is alkyl; -R Q4B is independently -F, -Cl, -Br, or -I; -R Q4C -CF 3 and -R Q5 are independently -H, -R Q5A , -R Q5B , or -R Q5C and -R Q5A is a saturated linear or branched chain C 1-4 is alkyl; -R Q5B is independently -F, -Cl, -Br, or -I; -R Q5C -CF 3 and -R P1 are independently -H or -R P1X and -R P1X is independently -R P1A , -R P1B , -R P1C , or -R P1D and -R P1A is a saturated linear or branched chain C 1-4 is alkyl; -R P1B is independently -F, -Cl, -Br, or -I; -R P1C -CF 3 and -R P1D are independently -NH 2 , -NHR P1DD , or -NR P1DD 2 and -R P1DD is a saturated linear or branched chain C 1-4 is alkyl; -R P2 are independently -H or -R P2X and -R P2X is independently -R P2A , -R P2B , -R P2C , or -R P2D and -R P2A is a saturated linear or branched chain C 1-4 is alkyl; -R P2B is independently -F, -Cl, -Br, or -I; -R P2C -CF 3 and -R P2D are independently -NH 2 , -NHR P2DD , or -NR P2DD 2 and -R P2DD is a saturated linear or branched chain C 1-4 is alkyl; -R A are independently -H or -R AA and -R AA are independently saturated linear or branched chain C 1-4 alkyl, phenyl, or benzyl) and a pharma- ceutically acceptable carrier, diluent, or excipient.

2. -R Q1 -R Q1A That is, The pharmaceutical composition of claim 1.

3. -R Q2 -R Q2A That is, The pharmaceutical composition according to claim 1 or 2.

4. -R Q3 is -H, The pharmaceutical composition according to any one of claims 1 to 3.

5. -R Q4 is -H, The pharmaceutical composition according to any one of claims 1 to 4.

6. -R Q5 is -H, The pharmaceutical composition according to any one of claims 1 to 5.

7. -R Q1A But, -Me, The pharmaceutical composition according to any one of claims 1 to 6.

8. -R Q2A But, -Me, The pharmaceutical composition according to any one of claims 1 to 7.

9. -R P1 is -H, The pharmaceutical composition according to any one of claims 1 to 8.

10. -R P2 is -H, The pharmaceutical composition according to any one of claims 1 to 9.

11. -R A is -H, The pharmaceutical composition according to any one of claims 1 to 10.

12. -R Q3 is -H, -R Q4 is -H, -R Q5 is -H, -R P1 is -H, -R P2 is -H, and -R A is -H, The pharmaceutical composition according to any one of claims 1 to 11.

13. The compound has one of the following formulas, or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: 【Chemistry 2】 【change】 【change】 That is, The pharmaceutical composition of claim 1.

14. The compound is of the following formula: or a pharma- ceutically acceptable salt, hydrate, or solvate thereof: 【Chemistry 3】 That is, The pharmaceutical composition of claim 1.

15. Neuropathic pain is: Peripheral neuropathic pain; Central neuropathic pain; Chronic neuropathic pain; Intractable neuropathic pain; Neuropathic pain associated with diabetes; Neuropathic pain associated with prediabetes; Neuropathic pain associated with painful polyneuropathy; Neuropathic pain associated with painful diabetic neuropathy; Neuropathic pain associated with diabetic peripheral neuropathy; Neuropathic pain associated with painful diabetic polyneuropathy; Neuropathic pain associated with postherpetic neuralgia; Neuropathic pain associated with trigeminal neuralgia; Neuropathic pain associated with occipital neuralgia; Neuropathic pain associated with painful radiculopathy; Neuropathic pain associated with lumbar or cervical painful radiculopathy; Neuropathic pain associated with infectious diseases; Neuropathic pain associated with herpes zoster (shingles), HIV infection, Lyme disease, diphtheria or leprosy; Neuropathic pain associated with liver or kidney disorders; Neuropathic pain associated with chronic liver or kidney damage; Neuropathic pain associated with liver disease, liver failure, kidney disease, or kidney failure; Neuropathic pain associated with immune or inflammatory disorders; Neuropathic pain associated with Guillain-Barre syndrome, rheumatoid arthritis, lupus, Sjogren's syndrome, or celiac disease; Neuropathic pain associated with inherited neuropathies or channelopathies; Neuropathic pain associated with hereditary erythromelalgia, paroxysmal acute pain, or Charcot-Marie-Tooth disease (CMT); Neuropathic pain associated with small fiber sensory neuropathy; Neuropathic pain associated with thyroid hormone disorders; Neuropathic pain associated with hypothyroidism; Neuropathic pain following stroke; Cancer-related neuropathic pain; Neuropathic pain associated with lymphoma or multiple myeloma; chemotherapy-associated neuropathic pain; Neuropathic pain associated with cancer chemotherapy; Neuropathic pain associated with peripheral nerve injury pain; Neuropathic pain associated with post-traumatic nerve damage; Neuropathic pain associated with post-traumatic neuropathy; Neuropathic pain following spinal cord injury; Neuropathic pain associated with spinal cord injury caused by trauma; Neuropathic pain secondary to traumatic peripheral nerve injury; Neuropathic pain secondary to post-surgical neuropathy; Postoperative neuropathic pain; Neuropathic pain after neurosurgery; Neuropathic pain after spinal surgery; Neuropathic pain associated with fibromyalgia; Neuropathic pain associated with low back pain; Neuropathic pain associated with carpal tunnel syndrome; Neuropathic pain accompanied by burning pain; Neuropathic pain associated with reflex sympathetic dystrophy (RSD); Neuropathic pain associated with complex regional pain syndrome (CRPS); Neuropathic pain associated with amputation; Neuropathic pain associated with neurodegenerative diseases; Neuropathic pain associated with Parkinson's disease; Neuropathic pain following stroke; Neuropathic pain associated with syringomyelia; Neuropathic pain associated with demyelinating diseases; Neuropathic pain associated with multiple sclerosis, transverse myelitis, or neuromyelitis optica; or Idiopathic neuropathic pain That is, The pharmaceutical composition according to any one of claims 1 to 14.

Citation Information

Patent Citations

  • factor

    JP2002540164A

  • Compounds exhibiting activity at the retinoic acid receptor

    JP2009501721A

  • Compositions and methods for muscle repair and regeneration

    JP2013536855A

  • Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarβ) agonists

    JP2017537967A

  • Methods of treating neuropathic pain with retinoic acid receptor agonists

    WO2008057930A2